Repositioning Immunotherapy in VetArans With Lung Cancer

Recruiting now · Phase 2

Conditions studied: Non-Small Cell Lung Cancer

In brief

This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

Key facts

Study ID

NCT06275360

Run by

VA Office of Research and Development

People needed

25

Starts

2024-03-01

Expected to finish

2030-03-31

Last updated by the study team

2026-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient must have a performance status of 0-1 (ECOG Performance Scale)
• Patient must be a candidate for concurrent chemoradiation
• Unresectable Stage III NSCLC as assessed by investigator or multidisciplinary tumor board assessment
• PD-L1 tumor expression greater than or equal to 1%
• Presence of measurable disease according to RECIST v1.1
• Adequate organ function
• Available tissue (archival FFPE preferred) with adequate tumor content ( 20% tumor cellularity)

You may not qualify if…

• Active autoimmune disease that has requires immunosuppressive therapy in the previous year
• Uncontrolled primary or acquired immunodeficiency (including HIV)
• Baseline corticosteroid usage (>10 mg prednisone or equivalent daily) aside from supportive medication use
• Tumor with known EGFR, ALK, ROS1, MET or RET mutations/fusions
• Presence of significant comorbidities precluding participation in a clinical study as determined by investigator
• Prior thoracic radiotherapy or prior systemic treatment for stage IIIB/IV NSCLC
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
• Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with informed consent through 180 days after the last dose of trial treatment
• Has a known history of active TB (Bacillus Tuberculosis)
• Has known active Hepatitis B or Hepatitis C
• Has received a live vaccine within 30 days of enrollment
• Known diagnosis of Interstitial Lung Disease
• Inability to provide informed consent

Where it is running

• VA Connecticut Healthcare System West Haven Campus, West Haven, CT — West Haven, Connecticut, United States (enrolling)
• VA Central Office, Washington, DC — Washington D.C., District of Columbia, United States (enrolling)
• Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana, United States (enrolling)
• VA Ann Arbor Healthcare System, Ann Arbor, MI — Ann Arbor, Michigan, United States (enrolling)
• Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE — Omaha, Nebraska, United States (enrolling)
• Michael E. DeBakey VA Medical Center, Houston, TX — Houston, Texas, United States (enrolling)
• Richmond VA Medical Center, Richmond, VA — Richmond, Virginia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.